
You could hear a pin drop. Shareholders of Resverlogix waited with baited breath for November 17th. That was the day that Resverlogix President and CEO Donald McCaffrey was to present data from the company’s ASSURE trial. In that study, which was completed earlier this year, just under three hundred patients with coronary artery disease took [...]







